|1.||Fichna, Jakub: 5 articles (02/2015 - 12/2002)|
|2.||Janecka, A: 4 articles (11/2012 - 09/2003)|
|3.||Janecka, Anna: 4 articles (08/2010 - 12/2002)|
|4.||Mirowski, M: 3 articles (04/2005 - 09/2003)|
|5.||Mirowski, Marek: 3 articles (01/2005 - 12/2002)|
|6.||Fichna, J: 2 articles (04/2005 - 09/2003)|
|7.||Wiercioch, R: 2 articles (05/2004 - 09/2003)|
|8.||Mokrowiecka, Anna: 1 article (02/2015)|
|9.||Cygankiewicz, Adam I: 1 article (02/2015)|
|10.||Krajewska, Wanda M: 1 article (02/2015)|
01/01/2013 - "Results show that administration of MCRT by i.v. or i.c.v. injection could induce bradycardia and decrease in mean arterial pressure (MAP) at a greater degree than that with morphiceptin and PFRTic-NH(2). "
08/01/1983 - "Administration of the morphiceptin analogue eliminated the conditioned bradycardia to the tone but not the acceleration to the shock. "
11/15/1982 - "Injections of the relative mu agonists Morphine and Morphiceptin the delta agonist D-Ala2, D-Leu5-Enkephalin (DADL) or the putative kappa agonist Dynorphin 1-13 into the HPV caused hypotension and bradypnea; Morphine produced tachycardia while DADL and Dynorphin bradycardia. "
05/01/2004 - "Uptake of radiolabeled morphiceptin and its analogs by experimental mammary adenocarcinoma: in vitro and in vivo studies."
09/01/2003 - "Synthesis of novel morphiceptin analogues modified in position 3 and their binding to mu-opioid receptors in experimental mammary adenocarcinoma."
09/01/2003 - "Binding of the (125)I-labeled mu-opioid receptor selective ligands, morphiceptin (Tyr-Pro-Phe-Pro-NH(2)) and [D-Phe(3)]morphiceptin, to membranes isolated from experimental mouse mammary adenocarcinoma was examined in vitro using a cross-linking assay followed by a Western blot technique. "
01/01/2005 - "The binding studies with membranes of mouse mammary adenocarcinoma cells have shown significantly higher Bmax values for endomorphin-1 and endomorphin- 2 (806 and 671, respectively) than for morphiceptin (131), a well-known specific micro-opioid receptor ligand. "
04/01/2005 - "The highest accumulation in the tumor was observed for [d-1-Nal3)morphiceptin, which reached the value of 8.19 +/- 1.14% dose/g tissue."
12/01/2002 - "Finally, new developments in the control of tumour growth and cell proliferation by morphiceptin analogues are surveyed, which open future perspectives in the diagnosis and treatment of various cancers."
09/01/2003 - "A series of new morphiceptin analogues, modified at the pharmacophoric position 3, was synthesized in order to find the correlation between the lipophilicity, electronic and steric properties of the amino acid in this position and the in vitro affinity of new analogues for mu-opioid receptors on mouse brain and tumor membranes. "
11/01/2012 - "In the present study, we examined the effect of the mu-opioid receptor selective peptide, morphiceptin, and its two synthetic analogs on mRNA and protein levels of MMP-9 and uPA in three human cancer cell lines: MCF-7, HT-29, and SH-SY5Y. "
|1.||mu Opioid Receptors (mu Opioid Receptor)
|2.||Messenger RNA (mRNA)
|3.||Morphine (MS Contin)
|5.||Opioid Receptors (Opioid Receptor)
|10.||beta-Endorphin (Endorphin, beta)